Optical Express Group claims good patient outcomes

Article

Recent research by the Optical Express Group says it has revealed that of 32,000 clients surveyed following treatment in 2009, 89 per cent achieved 20/16 vision or better.

Recent research by the Optical Express Group says it has revealed that of 32,000 clients surveyed following treatment in 2009, 89 per cent achieved 20/16 vision or better. The business has also recently made a $12 million investment installing iFS 150 femtosecond laser systems in all its 44 treatment clinics in the UK.

Commenting on the trend towards better than 20/20 outcomes Dr Steve Schallhorn, Medical Director and Chair of the International Medical Advisory Board for Optical Express said: “What we have reported is that our highly skilled surgeons using the very latest advancements in LASIK technology, consistently results in most patients achieving better than 20/20 unaided vision. These outcomes are phenomenal and testament to the medical and surgical care provided by Optical Express. It is also setting a new world-wide standard for laser eye surgery procedure outcomes.

“From a very early stage, Optical Express decided to lead from the front by advancing the frontiers of laser eye surgery. Together with the greatest experience in ophthalmology, our International Medical Advisory Board is second to none and is driving up standards to deliver safe and effective eye surgery with high levels of patient satisfaction.

“We continue to have very high levels of satisfaction among our patients. This is evidenced through our growth over the last year, during a time of deep economic turmoil.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.